Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial-Reference-Cited by-同舟云学术

Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial

Published:2021-04-01 Issue:4 Volume:31 Page:607-615
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Lin Yan-Song¹,Yang Hui²,Ding Yong³,Cheng Yi-Zhuang⁴,Shi Feng⁵,Tan Jian⁶,Deng Zhi-Yong⁷,Chen Zhen-Dong⁸,Wang Rong-Fu⁹,Ji Qing-Hai¹⁰,Huang Rui¹¹,Li Lin-Fa¹²

Affiliation:

1. Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, China.

2. Department of Nuclear Medicine, Henan Cancer Hospital, Zhengzhou, China.

3. Department of Nuclear Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.

4. Department of Nuclear Medicine, Anhui Provincial Hospital, Hefei, China.

5. Internal Medicine Department of Thyroid and Radionuclide Therapy, Hunan Cancer Hospital, Changsha, China.

6. Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, China.

7. Department of Nuclear Medicine, Yunnan Cancer Hospital, Kunming, China.

8. Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, China.

9. Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.

10. Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.

11. Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, China.

12. Department of Nuclear Medicine, Zhejiang Cancer Hospital, Hangzhou, China.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2020.0235

Reference21 articles.

1. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries

2. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

3. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma

4. Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy

5. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early Structural, Biochemical, and Metabolic Responses to Anlotinib in Patients With Progressive Radioactive Iodine Refractory Differentiated Thyroid Cancer;Endocrine Practice;2024-05

2. Donafenib as neoadjuvant therapy in locally advanced thyroid cancer: protocol for the DONATHYCA phase II prospective single-arm trial in China;BMJ Open;2024-05

3. Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer;Life;2023-12-22

4. Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer;Medical Oncology;2023-07-31

5. Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-07